Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned an average recommendation of “Moderate Buy” from the twenty-two ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $118.0952.

Several research firms recently commented on KYMR. UBS Group lifted their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Stephens boosted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Citigroup boosted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Piper Sandler boosted their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $74.13 on Friday. The firm’s 50 day simple moving average is $83.01 and its 200 day simple moving average is $79.70. Kymera Therapeutics has a one year low of $36.65 and a one year high of $103.00. The company has a market cap of $6.10 billion, a PE ratio of -20.76 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same period last year, the company earned ($0.82) EPS. The firm’s revenue was up 55.5% compared to the same quarter last year. Equities research analysts expect that Kymera Therapeutics will post -3.3 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In other news, COO Jeremy G. Chadwick sold 91,250 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $77.41, for a total value of $7,063,662.50. Following the transaction, the chief operating officer owned 61,202 shares in the company, valued at approximately $4,737,646.82. The trade was a 59.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elena Ridloff sold 7,400 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $85.37, for a total transaction of $631,738.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 260,115 shares of company stock worth $21,218,138. Company insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after purchasing an additional 1,833 shares during the period. Millennium Management LLC increased its stake in shares of Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after acquiring an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after acquiring an additional 491,737 shares in the last quarter. Invesco Ltd. increased its stake in shares of Kymera Therapeutics by 13.8% in the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock valued at $2,090,000 after acquiring an additional 5,809 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at $265,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.